The FDA approved Vertex Pharmaceuticals' Kalydeco to treat cystic fibrosis in patients age 6 and older with gene mutation G551D. The drug costs $294,000 annually.
Vertex's CF drug Kalydeco gets FDA approval
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan